NCT03074032View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
DRUG

ONC1-0013B

ONC1-0013B per os daily

Trial Locations (2)

105426

Research Institute of Urology and Interventional Radiology n.a. N.A. Lopatkin (branch of FSBI NMRRC of the Ministry of Health of the Russian Federation), Moscow

249036

Medical Radiological Research Center n.a. A.F. Tsyb (branch of FSBI NMRRC of the Ministry of Health of the Russian Federation), Obninsk

All Listed Sponsors
lead

Avionco LLC

INDUSTRY

NCT03074032 - Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer | Biotech Hunter | Biotech Hunter